New research continues to deepen the field’s understanding of skin barrier biology, neuroimmune interactions, and inflammatory mechanisms. These scientific advances are exciting and can benefit from accessible, high‑quality platforms to translate them into clinical practice and improve patient outcomes. Keeping this in mind, this year’s SKIN annual summit expanded beyond its previous focus on atopic dermatitis and prurigo nodularis to encompass a broader spectrum of inflammatory skin diseases.
Galderma reports strong start to the year, delivering first quarter 2026 net sales of 1.473 billion USD, growing 25.5% at constant currency.
Galderma is launching the Regenerating Skin Nectar with TriHex+™, the newest innovation from Alastin, a leader in peptide-based regenerative skincare. This innovation underscores Galderma’s commitment to advancing peri-procedural skincare and empowering providers with science-based solutions designed to deliver exceptional aesthetic and procedural outcomes.
Galderma welcomes new data from two IITs, demonstrating the power of Sculptra – the first proven regenerative biostimulator – and the company’s versatile hyaluronic acid injectable Restylane range, in addressing the aesthetic changes associated with menopause and medication-driven weight loss, for the face and body. Data includes an analysis from a first-of-its-kind study evaluating optimal treatment sequencing to enhance women’s skin during menopause, and an evaluation of the cellular makeup of fat in the abdomen following medication-driven weight loss.
Galderma today announced the launch of ALASTIN Signature Practices, a new designation for dermatology, plastic surgery, and medical aesthetics practices that integrate ALASTIN’s comprehensive regenerative skincare portfolio into treatment planning and patient care. Colorado Springs Dermatology Clinic is the first ALASTIN Signature Practice, with additional Signature Practices planned across the United States in 2026.
Galderma has anounced that the U.S. FDA has approved Restylane Contour for the correction of temple hollowing in patients over the age of 21. This builds on its previous approvals for cheek augmentation and midface contour deficiencies, helping injectors address volume loss across key structural areas. With the broadest Injectable Aesthetics portfolio in the industry, this follows the recent U.S. approval of Restylane Lyft for augmentation of the chin region, adding to its indications to treat the midface, facial folds and wrinkles, back of hands, and the chin. Together, these approvals demonstrate Galderma’s ongoing commitment to evolving the versatile Restylane portfolio to deliver personalized, natural-looking outcomes that meet diverse patient needs.
Galderma presented the latest updates on its innovative cross-dermatology portfolio at the 2026 American Academy of Dermatology (AAD) Annual Meeting, from March 27-31 in Denver, Colorado. Twenty-two abstracts were presented, including late-breaking data and three oral presentations spanning Therapeutic Dermatology, Injectable Aesthetics, and Dermatological Skincare.
Galderma will present nine abstracts at the Aesthetic & Anti‑Aging Medicine (AMWC) World Congress 2026 in Monaco, showcasing innovative and robust scientific data across its aesthetics portfolio, alongside three symposia, and multiple Masterclasses and Meet‑the‑Expert sessions, all highlighting the expanding benefits of Sculptra®, Relfydess® (RelabotulinumtoxinA) and the Restylane® range.
Galderma’s Global Sensitive Skincare Faculty (GSSF) carried out a clinical study that enrolled 150 women from China aged 35–50 to discover the causes and triggers of sensitive skin. These women represented three distinct profiles: those with a modern lifestyle and sensitive skin; those with a modern lifestyle and non-sensitive skin; and those with a traditional lifestyle and sensitive skin. Data from the study demonstrated a link between modern living—including stress, pollution and lack of sleep—and sensitive skin.
Galderma today announced Cetaphil, the dermatologist-recommended brand trusted by millions with sensitive skin, is launching its new Cetaphil AM/PM Antioxidant Serums, a breakthrough daily system clinically designed to defend skin by day and support accelerated repair by night for sensitive, stressed skin.
